Wegovy 1.7 mg Prefilled Pen

Wegovy 1.7 mg Prefilled Pen

Wegovy 1.7 mg FlexTouch is a prefilled pen containing semaglutide, a GLP-1 receptor agonist used as part of a comprehensive treatment programme for eligible patients. It is used alongside a reduced-calorie diet and increased physical activity.

The 1.7 mg strength is normally part of the dose-escalation schedule before the standard 2.4 mg once-weekly maintenance dose. Wegovy is a UK prescription-only medicine and should only be used according to the instructions of a qualified healthcare professional.

How Wegovy 1.7 mg Works

Semaglutide acts on GLP-1 receptors involved in appetite regulation. It can help increase feelings of fullness and reduce hunger and food cravings, supporting reduced food intake when combined with appropriate dietary and lifestyle measures.

Wegovy 1.7 mg Dose Information

For weight management, the current UK dosing schedule gradually increases the weekly dose:

Period	Weekly dose
Weeks 1–4	0.25 mg
Weeks 5–8	0.5 mg
Weeks 9–12	1 mg
Weeks 13–16	1.7 mg
From week 17	2.4 mg maintenance dose

The dose should only be increased according to the treatment plan provided by your prescriber. If significant gastrointestinal symptoms occur, a healthcare professional may advise delaying escalation or returning temporarily to the previous dose.

Who May Be Prescribed Wegovy?

UK prescribing information includes Wegovy for weight management in eligible adults with obesity or overweight with weight-related health problems, alongside diet and physical activity. It also has specific authorised uses in certain adults and adolescents. Eligibility should be assessed by a healthcare professional.

Important Safety Information

• Wegovy is a prescription-only medicine.
• Use it exactly as prescribed by your doctor, pharmacist or other qualified healthcare professional.
• Do not use Wegovy together with another semaglutide-containing medicine or another GLP-1 receptor agonist unless specifically instructed by your healthcare professional.
• Common side effects can include nausea, vomiting, diarrhoea, constipation, abdominal pain, headache and tiredness.
• Seek urgent medical attention for severe, persistent abdominal pain, which may be a sign of acute pancreatitis.
• Tell your healthcare professional if you have diabetes or take insulin or a sulfonylurea.
• Wegovy should not be used during pregnancy. Discuss pregnancy plans with your healthcare professional.

Wegovy 1.7 mg Prefilled Pen Information

• Active ingredient: Semaglutide
• Strength: 1.7 mg per dose
• Administration: Subcutaneous injection
• Frequency: Once weekly, as prescribed
• Pen type: FlexTouch prefilled pen
• Pen contents: Four 1.7 mg doses
• Prescription status: Prescription-only medicine (POM)

The 1.7 mg FlexTouch pen contains 6.8 mg of semaglutide in 3 mL solution and provides four prescribed 1.7 mg doses.

Related Wegovy Products

If you are following the standard dose-escalation pathway, you may also wish to review the Wegovy 1.0 mg Prefilled Pen and Wegovy 2.4 mg Prefilled Pen. You can also explore the complete Wegovy Products range.

For general information about weight management, visit our Weight Management Guide.

Official UK Medicine Information

For the latest official prescribing and patient information, consult the Wegovy 1.7 mg Patient Information Leaflet on eMC. The UK eMC information confirms the medicine contains semaglutide and is prescription-only.

Frequently Asked Questions

What is Wegovy 1.7 mg?

Wegovy 1.7 mg is a semaglutide prefilled injection pen used as part of the dose-escalation schedule for eligible patients receiving Wegovy treatment.

Is Wegovy 1.7 mg a prescription medicine?

Yes. Wegovy is classified as a prescription-only medicine in the UK.

How often is Wegovy 1.7 mg used?

Wegovy is administered once weekly according to the treatment plan prescribed by a healthcare professional.

Is 1.7 mg the maintenance dose?

For the standard adult weight-management schedule, 1.7 mg is an escalation dose. The usual maintenance dose is 2.4 mg once weekly.

Can I start directly with Wegovy 1.7 mg?

The standard dosing schedule begins at 0.25 mg and increases gradually. Do not start at 1.7 mg unless this has specifically been prescribed or advised by your healthcare professional.

Can Wegovy 1.7 mg be used with another GLP-1 medicine?

Wegovy should not be combined with another GLP-1 receptor agonist or another semaglutide-containing medicine unless specifically directed by a healthcare professional.

Where can I find official information about Wegovy?

The UK electronic Medicines Compendium (eMC) provides the official Patient Information Leaflet and Summary of Product Characteristics for Wegovy.